Ecraprost

Drug Profile

Ecraprost

Alternative Names: Circulase™

Latest Information Update: 06 Jun 2006

Price : $50

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Class Prostaglandins
  • Mechanism of Action Prostaglandin E1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic neuropathies; Intermittent claudication; Peripheral arterial disorders; Peripheral arterial occlusive disorders; Reperfusion injury

Most Recent Events

  • 11 May 2006 Discontinued - Phase-II for Peripheral arterial occlusive disorders in Japan (unspecified route)
  • 11 May 2006 Discontinued - Phase-III for Peripheral arterial occlusive disorders in USA (unspecified route)
  • 06 Dec 2004 This compound is still in active development for Peripheral Arterial Occlusive Disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top